Posturography-Neuropathy (PONE)

University Hospital, Lille

Status: Enrolling

Conditions: Neuropathy Demyelinating

Treatments: Other: Motion analysis

Study type: Interventional

Funder types: Other

Identifiers

NCT04154540

2017_17

2017-A02861-52 (Other Identifier)

Details and patient eligibility

About

If the classification between hereditary and acquired neuropathy is often easy, there is no completely specific marker allowing the distinction between the two etiologies. Clinical experience suggests that hereditary neuropathies have less impact on balance and gait than the acquired neuropathies at equivalent level of impairment, but this has never been clearly demonstrated.

Enrollment: 52 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• CMT1A for molecular-proven Group 1 (PMP22 duplication)
• IPDC likely or defined for Group 2
• Able to walk 10 m unassisted

Exclusion criteria

• Neurological history other than neuropathy: epilepsy, stroke, dementia
• Pregnant women
• Person under guardianship or trusteeship
• Musculoskeletal conditions other than neuropathy impairing walking abilities
• Major comorbidity considered a contraindication by the investigator (cancer, unstable angor, etc.)

Trial design

Primary purpose: Other

Allocation: Non-Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

52 participants in 2 patient groups

demyelinating hereditary neuropathy

Experimental group

Description:

adult patients with demyelinating hereditary neuropathy type CMT 1A.

Treatment:

Other: Motion analysis

demyelinating inflammatory neuropathy

Experimental group

Description:

adult patients with acquired demyelinating inflammatory neuropathy.

Treatment:

Other: Motion analysis